Early treatment of lupus helps improve outcomes for patients. Finding better blood tests to predict what is about to happen with lupus disease activity could alert doctors to changes in a patient’s condition that otherwise might not be obvious.
Investigators at UCLA believe they have discovered an antibody in the blood, MAGE-B2, which may be associated with lupus kidney disease in children and could possibly serve as a biomarker. If future studies continue to show an association between the MAGE-B2 antibody and lupus, or even more particularly lupus nephritis, doctors should be able to treat lupus earlier to prevent damage.
Investigators at UCLA believe they have discovered an antibody in the blood, MAGE-B2, which may be associated with lupus kidney disease in children and could possibly serve as a biomarker. If future studies continue to show an association between the MAGE-B2 antibody and lupus, or even more particularly lupus nephritis, doctors should be able to treat lupus earlier to prevent damage.
Read more about this study.